Daniel J. Hicklin is an employee of Imclone Systems.
Tyrosine kinase receptor RON in human pancreatic cancer
Expression, function, and validation as a target
Article first published online: 20 FEB 2007
Copyright © 2007 American Cancer Society
Volume 109, Issue 6, pages 1030–1039, 15 March 2007
How to Cite
Camp, E. R., Yang, A., Gray, M. J., Fan, F., Hamilton, S. R., Evans, D. B., Hooper, A. T., Pereira, D. S., Hicklin, D. J. and Ellis, L. M. (2007), Tyrosine kinase receptor RON in human pancreatic cancer. Cancer, 109: 1030–1039. doi: 10.1002/cncr.22490
- Issue published online: 7 MAR 2007
- Article first published online: 20 FEB 2007
- Manuscript Accepted: 30 NOV 2006
- Manuscript Revised: 5 NOV 2006
- Manuscript Received: 4 OCT 2006
- National Institutes of Health. Grant Numbers: T32 CA 09599, CA 16672
- Cancer Center Support Grant
- Lockton Fund for Pancreatic Cancer Research
- macrophage stimulating protein;
- pancreatic cancer, tyrosine kinase receptor
Specific tyrosine kinase receptors such as c-MET mediate epithelial-mesenchymal (EMT) transition, leading to phenotypic alterations associated with increased cell motility. It was hypothesized that RON, a tyrosine kinase receptor related to c-MET, would be expressed in human pancreatic cancer cells, induce EMT, and would thus serve as a target for therapy in a preclinical model.
RON expression in human pancreatic cancer specimens was assessed by immunohistochemistry. In pancreatic cancer cell lines, RON expression was assessed by reverse-transcriptase polymerase chain reaction (PCR) and Western blot analysis. The human pancreatic cancer cell line L3.6pl, with high RON expression, was exposed to macrophage stimulating protein (MSP), the RON ligand, and assessed for cell migration, invasion, and changes associated with EMT. Western blot analysis and immunofluorescent staining were used to assess alterations in protein expression and cellular location, respectively. A RON monoclonal antibody (MoAb) was used to block ligand-induced activation of RON.
Immunohistochemical staining revealed RON overexpression in 93% of human pancreatic cancer specimens relative to nonmalignant ductal tissue. RON mRNA and protein was expressed in 9 of 9 human pancreatic cancer cell lines. Treatment of L3.6pl cells with MSP increased Erk phosphorylation, cell migration, and invasion (P < .001). RON activation led to a decrease in membrane-bound E-cadherin in association with nuclear translocation of β-catenin. RON MoAb inhibited downstream signaling as well as cell migration and invasion. In nude mice, RON MoAb inhibited subcutaneous and orthotopic tumor growth by about 60%.
RON activation induced molecular and cellular alterations consistent with EMT. Inhibition of RON activation inhibited tumor growth in vivo. Novel antineoplastic therapies designed to inhibit RON activity may hinder mechanisms critical for pancreatic tumor progression. Cancer 2007 © 2007 American Cancer Society.